Genisphere Awarded Patent for Cellular Delivery of siRNA and other Therapeutics using 3DNA® Nanocarrier

The patent includes claims for keeping the company's DNA-based therapeutic nanocarrier (trademarked 3DNA®) intact in a living system. Physical protection of siRNA and other drug cargo is also claimed in the patent, when these therapeutic molecules are delivered using the 3DNA® nanocarrier. This patent is part of Genisphere's "Long-acting DNA dendrimers and methods thereof" patent family which has issued composition of matter and methods claims covering a broad range of 3DNA®-based pharmaceutical compositions.

Based on the granted claims, Genisphere's coverage includes a variety of strategies to shield its 3DNA® from the harsh physiological environment often found in body fluids and tissues, as well as multiple approaches to attach siRNA to 3DNA® while maximizing the complex's ability to achieve the biological outcome. The patent extends coverage to other drug payloads, including DNA molecules, proteins, chemotherapeutics, antivirals, and hormones. 

Tom Bliss, Genisphere's Chief Executive Officer, said "This patent and overall patent family is a significant component of Genisphere's extensive intellectual property portfolio, since our nanocarrier is broadly adaptable to deliver a variety of active pharmaceutical ingredients. Our pharma partners will benefit from this protection when their drug is formulated with our delivery technology, and ultimately the patent life of their drug will be extended."